MedTrace Logo

TTAC-0001 Phase II Trial With Recurrent Glioblastoma Progressed on Bevacizumab

NCT03856099 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 19

Last updated 2022-08-18

No results posted yet for this study

Summary

This is a phase II, open-Label clinical trial to evaluate the safety and efficacy of TTAC-0001 in patients with recurrent glioblastoma who was progressed on bevacizumab including therapy.

Conditions

Interventions

DRUG

TTAC-0001

* Investigational product (IP): TTAC-0001 * Treatment groups: 3 dose groups * Dose group A : TTAC-0001 16 mg/kg on D1 and D15 * Dose group B : TTAC-0001 20 mg/kg on D1 and D15 * Dose group C : TTAC-0001 24 mg/kg on D1 and D15 * Cycle: 4 weeks (28 days per cycle)

Sponsors & Collaborators

  • PharmAbcine

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-13
Primary Completion
2022-07-15
Completion
2022-07-15
FDA Drug
Yes

Countries

  • United States
  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03856099 on ClinicalTrials.gov